ligand.comLigand Pharmaceuticals - Biopharma's Technology and Capital Partner

Overview Team Responsibility Our Approach Royalty Portfolio Key Commercial Products Key Pipeline Products Additional Products Licensing Investors News MenuOverview Team Responsibility Our Approach Royalty Portfolio Key Commercial Products Key Pipeline Products Additional Products Licensing Investors News Biopharma’s Technology and Capital Partner Technology and financing solutions to advance tomorrow’s medicines A specialist in healthcare investing Ligand invests in the clinical development and commercialization of high-value medicines. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 85 partnered commercial and development stage programs. We also maintain and license our Captisol® technology platform with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. Diversified Portfolio Our portfolio includes programs that span disease areas such as cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and many rare conditions. Today we own economic rights to more than 25 c ommercial programs , which are marketed in more than 70 countries. Explore Our Portfolio By the Numbers portfolio assets 0 + marketed products generating royalties 0 + active Captisol- partnered programs 0 + invested in 2023 $ 0 M+ All figures as of December 31, 2023, unless otherwise indicated. ZELSUVMI™ Receives U.S. FDA Approval The U.S. FDA approves ZELSUVMI™ as a first-in-class medication for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. Ligand Acquires Royalties on Sanofi’s TZIELD® Ligand acquires Tolerance Therapeutics for $20 million in cash including a royalty of less than 1% on worldwide net sales of TZIELD®. Ovid Therapeutics and Ligand Enter into $30 Million Agreement Ligand acquires royalties and milestones on Takeda’s soticlestat, a potential treatment for Lennox-Gastaut syndrome and Dravet syndrome. Latest News Ligand Reports First Quarter 2024 Financial Results May 7, 2024 Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement May 7, 2024 Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 April 23, 2024 Contents:Overview Team Responsibility Our Approach Royalty Portfolio Key Commercial Products Key Pipeline Products Additional Products Licensing Investors News MenuOverview Team Responsibility Our Approach Royalty Portfolio Key Commercial Products Key Pipeline Products Additional Products Licensing Investors News Register for Company Updates: Email Subscribe Careers Contact Careers Contact Linkedin Copyright © 2024 Ligand Pharmaceuticals Incorporated. All rights reserved. Privacy Terms of Use Privacy Terms of...